N-benzyl-6,7,8,9-tetrahydro-5H-benzo[7]annulen-7-amine | 312753-77-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-benzyl-6,7,8,9-tetrahydro-5H-benzo[7]annulen-7-amine
• 英文别名: benzyl-(6,7,8,9-tetrahydro-5H-benzocyclohepten-7-yl)-amine
• CAS: 312753-77-8
• 化学式: C₁₈H₂₁N
• 分子量: 251.371
• InChiKey: DPUYSZJVGFTTMX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-benzyl-6,7,8,9-tetrahydro-5H-benzo[7]annulen-7-amine 在 钯 作用下， 以 甲醇 为溶剂， 反应 24.0h， 生成 6,7,8,9-四氢-5H-苯并环庚烷-7-胺
  参考文献：
  名称：

  Beta-2-adrenoreceptor agonists

  摘要：

  该化合物以自由形式、盐形式或溶剂形式存在，其中Ar是公式的一组，Y是碳或氮，而R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、X、n、p、q和r在说明书中定义。该化合物的制备以及它们作为药物的用途，特别是用于治疗阻塞性或炎症性呼吸道疾病。

  公开号：

  US08436017B2
• 作为产物：
  描述：

  dimethyl 1,2,4,5-tetrahydro-3-oxobenzocycloheptene-2,4-dicarboxylate 在 盐酸 、 水 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 26.5h， 生成 N-benzyl-6,7,8,9-tetrahydro-5H-benzo[7]annulen-7-amine
  参考文献：
  名称：

  Synthesis, GluN2B affinity and selectivity of benzo[7]annulen-7-amines

  摘要：

  Due to their beneficial side effect profile, NMDA receptor antagonists interacting selectively with the allosteric ifenprodil binding site of the GluN2B subunit are of major interest for the treatment of neurological and neurodegenerative disorders. A series of benzo[7]annulen-7-amines 6 was designed by conformational restriction of ifenprodil (1). At first the benzo[7]annulen-7-one 11 was prepared in a three-step synthesis comprising of a double Knoevenagel condensation of phthalaldehyde (7) with dimethyl 3-oxoglutarate (8), hydrogenation of 9 and saponification/decarboxylation of 10. Reductive amination of the ketone 11 with primary amines and NaBH(OAc)(3) led to the secondary amines 6a-d, cis-6h and trans-6i. The tertiary amines 6e-g were obtained by S(N)2-substitution of the nosylate 13. Although H-bond forming substituents in 2- and 5-position are missing, the amines 6 exhibit high affinity towards GluN2B containing NMDA receptors. A distance of four to five bond lengths between the basic amino moiety and the phenyl ring in the side chain appears to be optimal for high GluN2B affinity. The phenylcyclohexylamine cis-6h and the 4-benzylpiperidine 6g show the highest GluN2B affinities (K-i = 2.3 nM and 2.9 nM, respectively). With respect to selectivity against the PCP binding site, sigma(1) and sigma(2) receptors the phenylpiperazine 6f is the most promising GluN2B antagonist. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.10.004

文献信息

• Do GluN2B subunit containing NMDA receptors tolerate a fluorine atom in the phenylalkyl side chain?
  作者：Yoshihiro Shuto、Simone Thum、Louisa Temme、Dirk Schepmann、Masato Kitamura、Bernhard Wünsch

  DOI：10.1039/c6md00621c

  日期：——

  fluorinated ligands 4 and 5 are almost identical. The low impact of the F-atom on GluN2B affinity was unexpected, as it influences several chemical and physicochemical properties of the ligands. However, introduction of the F-atom led to reduced selectivity over σ receptors. Whereas 5a and 5b display still a 2–3-fold preference for GluN2B over σ1 receptors, they show almost the same affinity to GluN2B and

  研究了苯并[7]环戊烯-7-胺侧链中的F原子对含NMDA受体的GluN2B亚基的亲和力和对相关受体的选择性的影响。5a和5b的合成是通过将酮6与在β位置带有F原子的伯烷胺14a和14b还原胺化来进行的。非氟化配体4和氟化配体5的GluN2B亲和力几乎相同。F原子对GluN2B亲和力的低影响是出乎意料的，因为它会影响配体的几种化学和物理化学性质。但是，引入F原子导致选择性降低。σ受体。而图5a和5b中显示仍然GluN2B 2-3倍优先于σ 1种受体，它们显示出几乎GluN2B和相同的亲和力σ 2个受体。
• Beta2-adrenoceptor agonists
  申请人：Cuenoud Bernard

  公开号：US06878721B1

  公开（公告）日：2005-04-12

  Compounds of formula in free or salt or solvate form, where Ar is a group of formula Y is carbon or nitrogen and R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , X, n, p, q and r are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of obstructive or inflammatory airways diseases.

  公式中的化合物以自由形式、盐或溶剂形式存在，其中Ar是化学式的一组，Y是碳或氮，R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、X、n、p、q和r如规范中所定义，它们的制备及其作为药物的用途，特别是用于治疗阻塞性或炎症性气道疾病。
• [EN] BETA2-ADRENOCEPTOR AGONISTS<br/>[FR] AGONISTES DU RECEPTEUR BETA 2-ADRENERGIQUE
  申请人：NOVARTIS AG

  公开号：WO2000075114A1

  公开（公告）日：2000-12-14

  Compounds of formula (I) in free or salt or solvate form, where Ar is a group of formula (II) Y is carbon or nitrogen and R?1, R2, R3, R4, R5, R6, R7, R8, R9, R10¿, X, n, p, q and r are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of obstructive or inflammatory airways diseases. The compounds of formula (I) in free, salt or solvate form, have β2-adrenoreceptor agonist activity.

  公式（I）的化合物，其自由形式、盐形式或溶剂化合物形式中，其中Ar是公式（II）的基团，Y是碳或氮，R?1，R2，R3，R4，R5，R6，R7，R8，R9，R10，X，n，p，q和r如规范所定义，它们的制备以及它们作为药物的用途，特别是用于治疗阻塞性或炎性呼吸道疾病。公式（I）的化合物在自由、盐或溶剂化合物形式中具有β2-肾上腺素受体激动剂活性。
• BETA-2-ADRENORECEPTOR AGONISTS
  申请人：Cuenoud Bernard

  公开号：US20100029705A1

  公开（公告）日：2010-02-04

  Compounds of formula in free or salt or solvate form, where Ar is a group of formula Y is carbon or nitrogen and R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , X, n, p, q and r are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of obstructive or inflammatory airways diseases.

  该化合物的化学式为自由或盐或溶剂形式，其中Ar是化学式的一组，Y是碳或氮，R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、X、n、p、q和r的定义在说明书中，其制备以及其作为药物的用途，特别是用于治疗阻塞性或炎症性呼吸道疾病。
• β2-adrenoceptor agonists
  申请人：Novartis AG

  公开号：US07622483B2

  公开（公告）日：2009-11-24

  Compounds of formula in free or salt or solvate form, where Ar is a group of formula Y is carbon or nitrogen and R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, X, n, p, q and r are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the treatment of obstructive or inflammatory airways diseases.

  公式为自由或盐或溶剂化合物，其中Ar是公式的一组，Y为碳或氮，而R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、X、n、p、q和r如规范中所定义，其制备和用途作为药物，特别是用于治疗阻塞性或炎症性呼吸道疾病。